Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jaclp.2023.04.005 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Low Frequency of Dementia with Lewy Bodies Diagnosis in a Colombian Memory Clinic.
Mov Disord Clin Pract
September 2025
Centre for Age-Related Medicine (SESAM), Stavanger University Hospital, Stavanger, Norway.
Background: The global burden of dementia is increasing, particularly in low- and middle-income countries. Dementia with Lewy bodies (DLB) is the second most common neurodegenerative dementia but remains underreported and frequently misdiagnosed. Its prevalence in Latin America is largely unknown.
View Article and Find Full Text PDFCognitive functions among Saudi patients with methamphetamine and cannabis use disorder.
Front Psychiatry
August 2025
Neuropsychiatry Department, Okasha Institute of Psychiatry, Ain Shams University, Cairo, Egypt.
Background: Methamphetamine use disorder (MUD) is linked to a variety of cognitive and neuropsychiatric deficits. One of the illegal substances that is most frequently abused is cannabis. The general consensus is that both recreational cannabis and methamphetamine use result in a wide spectrum of severe cognitive impairments, although there have been questions raised regarding conclusions derived from published material.
View Article and Find Full Text PDFTreatment modifiers and predictors of risperidone response in dementia: An individual participant data meta-analysis of six randomized controlled trials.
Alzheimers Dement
September 2025
School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Camperdown, Sydney, New South Wales, Australia.
Introduction: Risperidone is approved for behaviors and psychological symptoms of dementia (BPSD), despite modest efficacy and known risks. Identifying responsive symptoms, treatment modifiers, and predictors is crucial for personalized treatment.
Method: A one-stage individual participant data meta-analysis of six randomized controlled trials (risperidone: n = 1009; placebo: N = 712) was conducted.
Optimizing timing and dose of exogenous melatonin administration in neuropsychiatric pediatric populations: a meta-analysis on sleep outcomes.
Sleep Med Rev
August 2025
Department of Developmental Neuroscience, IRCCS Stella Maris Foundation, Viale Del Tirreno. 341/A/B/C, Calambrone, Pisa, 56128 Italy; Department of Translational Research and of New Surgical and Medical Technologies, University of Pisa, Via Savi 10, 56126, Pisa, Italy.
Melatonin is known to be effective in improving sleep in pediatric patients affected by neurological and psychiatric conditions. However, no guidelines exist advising the most effective treatment schedule. This systematic review and meta-analysis aimed to identify the dose, time of administration and treatment duration associated with the maximal treatment efficacy.
View Article and Find Full Text PDFPyridoxine supplementation for levetiracetam-related neuropsychiatric adverse events in pediatric and adolescent epilepsy: a prospective, double-blind, randomized, placebo-controlled trial.
Epilepsy Behav
September 2025
Neurology Division, Department of Pediatrics, Phramongkutklao Hospital, Bangkok, Thailand. Electronic address:
Background: Levetiracetam commonly causes neuropsychiatric adverse events (NPAEs) in pediatric patients, including irritability and aggression. This study evaluated pyridoxine supplementation for reducing levetiracetam-related NPAEs in children and adolescents with epilepsy.
Methods: We conducted a prospective, double-blind, randomized, placebo-controlled trial at Phramongkutklao Hospital, Thailand (January-June 2024).